ANB033 Early Signal Promising, But Phase 1 Data Cannot Carry Late-Stage Weight

First Tracks' ANB033 Shows Impressive Early Celiac Disease Data

First Tracks Biotherapeutics announced positive early-stage clinical data for its experimental drug ANB033 in celiac disease. The drug demonstrated a statistically significant improvement in protecting the intestinal lining from gluten-induced damage compared to placebo after six weeks of treatment. ANB033 also showed positive results on other measures of disease severity, prevented an increase in symptoms during a gluten challenge, and exhibited a clean safety profile with no serious adverse events or trial discontinuations. The company plans to report data from a second cohort next quarter and initiate a late-stage trial in 2027.

• ANB033 achieved statistically significant improvement in protecting the intestinal lining from gluten-induced damage, a key measure of celiac disease severity, compared to placebo. The drug also successfully prevented an increase in symptoms during a two-week gluten challenge, demonstrating its potential to offer protection beyond a gluten-free diet.
• The early-stage trial reported a "clean safety" profile for ANB033, with no serious adverse events related to treatment and no participants discontinuing the trial due to side effects. This robust safety data supports further development of the drug for celiac disease and potentially other autoimmune conditions.
• Beyond celiac disease, ANB033 is being investigated for "pipeline-in-a-product potential" across several autoimmune diseases, including a Phase 1b trial in eosinophilic esophagitis and planned Phase 2 development in vitiligo. First Tracks anticipates starting a late-stage trial for celiac disease in 2027, addressing a significant unmet need as celiac disease currently lacks an approved treatment.

ANB033's Phase 1b Data Shows Promise in Celiac Disease

Several recent clinical trials have advanced the understanding of non-dietary therapeutic strategies in celiac disease. In a proof-of-concept phase 2 trial of ZED1227, a selective oral transglutaminase 2 inhibitor developed by Dr. Falk Pharma, adults with well-controlled celiac disease underwent a daily gluten challenge for 6 weeks. Treatment with ZED1227 at all three dose levels (10 mg, 50 mg, and 100 mg) attenuated gluten-induced duodenal mucosal injury, with estimated differences from placebo in the change in mean villus height to crypt depth ratio of 0.44 (95% CI, 0.15 to 0.73) in the 10-mg group (P = .001), 0.49 (95% CI, 0.20 to 0.77) in the 50-mg group (P<.001), and 0.48 (95% CI, 0.20 to 0.77) in the 100-mg group (P<.001). The estimated differences from placebo in the change in intraepithelial lymphocyte density were -9.6 cells per 100 epithelial cells (95% CI, -14.4 to -4.8) in the 100-mg group. The most common adverse events — headache, nausea, diarrhea, vomiting, and abdominal pain — occurred at similar incidences across all groups, though rash developed in 3 of 40 patients (8%) in the 100-mg group.

A phase 2 gluten challenge trial of IMGX003 (latiglutenase), a 1200-mg dose of an orally administered mixture of 2 recombinant gluten-targeting proteases, enrolled 50 patients with celiac disease exposed to 2 g of gluten per day for 6 weeks, of whom 43 completed the study (IMGX003, n = 21; placebo, n = 22). The mean change in the ratio of villus height to crypt depth (primary endpoint) for IMGX003 vs placebo was -0.04 vs -0.35 (P = .057). For the secondary endpoint of intraepithelial lymphocyte density, the mean change for IMGX003 vs placebo was 9.8 vs 24.8 cells/mm epithelium (P = .018). The 3 × 2-week trend line significance values for symptom severity — abdominal pain, bloating, and tiredness — were P = .014, .030, and .002, respectively.

In a phase 1 dose-escalation study of Nexvax2, a peptide-based epitope-specific immunotherapy administered intradermally to HLA-DQ2·5 genotype-positive adults with celiac disease on a gluten-free diet, stepwise dose escalation from 3 μg successfully attenuated the first-dose effect that had previously limited the maximum tolerated dose to 150 μg. Escalation to 300 μg in HLA-DQ2·5 homozygotes and to 900 μg in non-homozygotes was achieved without the cytokine release or gastrointestinal symptoms observed with fixed dosing. Adverse events in Nexvax2-treated participants starting at 3 μg were comparable to placebo, and administration at dose levels from 150 μg to 900 μg preceded by dose escalation was not associated with elevations in plasma cytokines at 4 hours. The most common treatment-emergent adverse events across Nexvax2 participants were headache (52%), diarrhoea (48%), nausea (37%), abdominal pain (26%), and abdominal discomfort (19%), and Nexvax2 treatment was associated with trends towards improved duodenal histology.

ANB033: A New Horizon for Celiac Mucosal Protection

For individuals living with celiac disease, the cornerstone of management has long been a stringent, lifelong gluten-free diet. Yet, even with diligent adherence, many patients continue to experience persistent symptoms and, critically, often fail to achieve complete healing of the small intestinal mucosa. This ongoing mucosal damage, characterized by villous atrophy and increased intraepithelial lymphocytes, underscores a significant unmet need for therapies that can directly protect the gut from gluten's harmful effects.

The recent announcement from First Tracks Biotherapeutics regarding their experimental drug ANB033 offers a compelling glimpse into a potential paradigm shift. Early-stage clinical data indicate that ANB033 not only significantly improved the protection of the intestinal lining from gluten-induced damage but also positively impacted other measures of disease severity and prevented symptom exacerbation during a controlled gluten challenge. This direct intervention on the disease's pathophysiology, particularly the ability to mitigate mucosal injury, is a crucial step forward. While previous agents have shown promise in alleviating symptoms during gluten exposure, ANB033's focus on histological improvement suggests a more profound, disease-modifying potential.

However, the path to market is fraught with considerations. While the early safety profile is encouraging, larger, longer-term studies will be essential to fully understand the drug's long-term safety and potential for immunogenicity. Furthermore, translating efficacy observed in controlled gluten challenge settings to the complexities of real-world gluten exposure, where adherence to a gluten-free diet can be imperfect, will be a key challenge. The reliance on histological endpoints, while critical, also necessitates highly standardized and reproducible assessment methods across multi-center trials, given the known variability in such evaluations. Should ANB033 continue to demonstrate robust efficacy and safety in late-stage development, it could fundamentally reshape the therapeutic landscape for celiac disease, offering patients a much-needed option beyond dietary restrictions and potentially setting a new standard for achieving true mucosal healing.